Advanced search
Publication Cover
OncoImmunology Volume 5, 2016 - Issue 5
Submit an article Journal homepage
3,605
Views
112
CrossRef citations to date
0
Altmetric
Original Research

Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients

Yu SawadaDivision of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan;Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama, Japan
,
Toshiaki YoshikawaDivision of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan
,
Kazuya OfujiDivision of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan
,
Mayuko YoshimuraDivision of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan
,
Nobuhiro TsuchiyaDivision of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan;Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama, Japan
,
Mari TakahashiDivision of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan
,
Daisuke NobuokaDivision of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan;Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Kita-ku, Okayama, Japan
,
Naoto GotohdaDivision of Surgery, National Cancer Center, Hospital East, Kashiwa, Chiba, Japan
,
Shinichiro TakahashiDivision of Surgery, National Cancer Center, Hospital East, Kashiwa, Chiba, Japan
,
Yuichiro KatoDivision of Surgery, National Cancer Center, Hospital East, Kashiwa, Chiba, Japan
,
Masaru KonishiDivision of Surgery, National Cancer Center, Hospital East, Kashiwa, Chiba, Japan
,
Taira KinoshitaAichi Cancer Center Hospital, Chikusa-ku, Nagoya, Japan
,
Masafumi IkedaDivision of Hepatobiliary & Pancreatic Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
,
Kohei NakachiDivision of Hepatobiliary & Pancreatic Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
,
Naoya YamazakiDepartment of Dermatology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
,
Shoichi MizunoDivision of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan
,
Tadatoshi TakayamaDepartment of Digestive Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan
,
Kenji YamaoDepartment of Gastroenterology, Aichi Cancer Center Hospital, Chikusa-ku, Nagoya, Japan
,
Katsuhiko UesakaDivision of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center Hospital, Sunto- Nagaizumi, Shizuoka, Japan
,
Junji FuruseDepartment of Medical Oncology, Kyorin University School of Medicine, Mitaka-shi, Tokyo, Japan
,
Itaru EndoDepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama, Japan
&
Tetsuya NakatsuraDivision of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, JapanCorrespondence[email protected]
 show all
Article: e1129483 | Received 28 Oct 2015, Accepted 30 Nov 2015, Published online: 31 May 2016

References

  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi.org/10.3322/caac.20107
  • El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132:2557-76; PMID:17570226; http://dx.doi.org/10.1053/j.gastro.2007.04.061
  • Hanazaki K, Kajikawa S, Shimozawa N, Mihara M, Shimada K, Hiraguri M, Koide N, Adachi W, Amano J. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg 2000; 191:381-8; PMID:11030243; http://dx.doi.org/10.1016/S1072-7515(00)00700-6
  • Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y et al. Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors. Am J Gastroenterol 2012; 107:569-77; PMID:22158026; http://dx.doi.org/10.1038/ajg.2011.425
  • Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Toyoda H, Shimada S, Takahashi M et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997; 25:87-92; PMID:8985270; http://dx.doi.org/10.1002/hep.510250116
  • Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015; 16(13):1344-54; PMID:26361969; http://dx.doi.org/10.1016/S1470-2045(15)00198-9
  • Habu D, Shiomi S, Tamori A, Takeda T, Tanaka T, Kubo S, Nishiguchi S. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 2004; 292:358-61; PMID:15265851; http://dx.doi.org/10.1001/jama.292.3.358
  • Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996; 334:1561-7; PMID:8628336; http://dx.doi.org/10.1056/NEJM199606133342402
  • Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32:228-32; PMID:10915728; http://dx.doi.org/10.1053/jhep.2000.9409
  • Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356:802-7; PMID:11022927; http://dx.doi.org/10.1016/S0140-6736(00)02654-4
  • Kuang M, Peng BG, Lu MD, Liang LJ, Huang JF, He Q, Hua YP, Totsuka S, Liu SQ, Leong KW et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res 2004; 10:1574-9; PMID:15014006; http://dx.doi.org/10.1158/1078-0432.CCR-03-0071
  • Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306:16-25; PMID:12788060; http://dx.doi.org/10.1016/S0006-291X(03)00908-2
  • Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125:89-97; PMID:12851874; http://dx.doi.org/10.1016/S0016-5085(03)00689-9
  • Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009; 100:1403-7; PMID:19496787; http://dx.doi.org/10.1111/j.1349-7006.2009.01206.x
  • Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 2012; 18:3686-96; PMID:22577059; http://dx.doi.org/10.1158/1078-0432.CCR-11-3044
  • Sawada Y, Yoshikawa T, Fujii S, Mitsunaga S, Nobuoka D, Mizuno S, Takahashi M, Yamauchi C, Endo I, Nakatsura T. Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: An autopsy case. Human Vaccines and Immunotherapeutics. 2013; 9(7):1228-1233; PMID:23466818; http://dx.doi.org/10.4161/hv.24179
  • Suzuki S, Shibata K, Kikkawa F, Nakatsura T. Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports. Hum Vaccin Immunother 2013; 19:10(2):338–343; PMID: 24252799; http://dx.doi.org/10.4161/hv.27217
  • Zerbini A, Pilli M, Penna A, Pelosi G, Schianchi C, Molinari A, Schivazappa S, Zibera C, Fagnoni FF, Ferrari C et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res 2006; 66:1139-46; PMID:16424051; http://dx.doi.org/10.1158/0008-5472.CAN-05-2244
  • Mizukoshi E, Yamashita T, Arai K, Sunagozaka H, Ueda T, Arihara F, Kagaya T, Yamashita T, Fushimi K, Kaneko S. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma Hepatology 2013; 57(4):1448-57; PMID:23174905; http://dx.doi.org/10.1002/hep.26153
  • Nobuoka D, Motomura Y, Shirakawa H, Yoshikawa T, Kuronuma T, Takahashi M, Nakachi K, Ishii H, Furuse J, Gotohda N et al. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. Int J Oncol 2012; 40:63–70; PMID:21922136; http://dx.doi.org/10.3892/ijo.2011.1202
  • Yoshikawa T, Nakatsugawa M, Suzuki S, Shirakawa H, Nobuoka D, Sakemura N, Motomura Y, Tanaka Y, Hayashi S, Nakatsura T. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. Cancer Sci 2011; 102:918-25; PMID:21281401; http://dx.doi.org/10.1111/j.1349-7006.2011.01896.x
  • Pan K, Li YQ, Wang W, Xu L, Zhang YJ, Zheng HX, Zhao JJ, Qiu HJ, Weng DS, Li JJ et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol 2013; 20:4305-11; PMID:23892527; http://dx.doi.org/10.1245/s10434-013-3144-x
  • Sawada Y, Ofuji K, Sakai M, Nakatsura T. Immunotherapy for hepatocellular carcinoma: current status and future perspectives. In: Reeves H, Manas DM, Lochan R, eds. editors Liver Tumors - Epidemiology, Diagnosis, Prevention and Treatment. Rijeka: Intech, 2013. 59-90 p; http://dx.doi.org/10.5772/54594
  • Llovert JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. Journal of Hepatology 2008; 48:S20-S37; PMID:18304676; http://dx.doi.org/10.1016/j.jhep.2008.01.022
  • Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V, Groshen S, Weber J. Phase I trial of a MART-1 peptide vaccine with incomplete freund’s adjuvant for resected high-risk melanoma. Clin Cancer Res 1999; 5:2756-65; PMID:10537339
  • Slingluff CL Jr, Lee S, Zhao F, Chianese-Bullock KA, Olson WC, Butterfield LH, Whiteside TL, Leming PD, Kirkwood JM. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin Cancer Res 2013; 19:4228-38; PMID:23653149; http://dx.doi.org/10.1158/1078-0432.CCR-13-0002
  • Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8+ T cellsinduced by melanoma vaccines. Cancer Res 2014; 74(4):1045-55; PMID:24343228; http://dx.doi.org/10.1158/0008-5472.CAN-13-2908
  • Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med 2013; 19:465-72; PMID:23455713; http://dx.doi.org/10.1038/nm.3105
  • Salerno EP, Shea SM, Olson WC, Petroni GR, Smolkin ME, McSkimming C, Chianese-Bullock KA, Slingluff CL Jr. Activation, dissfunction and retention of T cell in vaccine sites after injection of incomplete Freund’s adjuvant, with or without peptide. Cancer Immunol Immunother 2013; 62:1149-59; PMID:23657629; http://dx.doi.org/10.1007/s00262-013-1435-5
  • Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005; 175:6169-76; PMID:16237114; http://dx.doi.org/10.4049/jimmunol.175.9.6169
  • Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin 2012; 62:309-335; PMID:22576456; http://dx.doi.org/10.3322/caac.20132
  • Sawada Y, Yoshikawa T, Shimomura M, Iwama T, Endo I, Nakatsura T. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int J Oncol 2015; 46:28-36; PMID:25354479; http://dx.doi.org/10.3892/ijo.2014.2737

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.